[Summary text]
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: onsecutive outpatients who received aDSM-IV-TR (36) diagnosis of BPD and then met criteria for amajor depressive episode (that is, mild to moderate).
Excluded criteria: We excluded individuals with a lifetime diagnosis of delir-ium, dementia, amnestic or other cognitive disorders, schizo-phrenia or other psychotic disorders, and patients whosemajor depressive episode was an expression of bipolardisorder.
Pretreatment: none
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Recidivrate, Længste follow-up (min. ½ år)
Livskvalitet
Responsrate, Efter endt behandling
Arbejdsfastholdelse, Længste follow-up (min. ½ år)
Funktionsevne (aktivitet og deltagelse), Længste follow-up (min. ½ år)
Sponsorship source: This study received no funding and no support
Country: Italien
Setting:
Comments:
Authors name: Bellino 2006
Institution:
Email:
Address:
Birgitte Holm Petersen on 31/08/2015 18:35
Select
I: IPT
Britta Tendal on 10/11/2015 04:32
Continuous Outcomes
No follow-up only end of treatment (24 weeks). They report on a scale called Satisfaction profile which they say measure a combination of quality of life and social functioning, but only at end of treatment as they have no FU
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma CBT (12-15 sessions)
Farma monobehandling
Included criteria: Responders to CBT+pharmacological treatment or pharmacological treatment in original study, primary major depressive disorder, unipolar and sos--psychotic subtype, BDI>=14
Excluded criteria: (non-responders to treatment in the original RCT)
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma CBT (12-15 sessions)
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Sponsorship source: None
Country: UK
Setting: Naturatistic follow-up, outpatient clinics
Comments: This is a follow up study of remission and relapse rates over 2 years after successful treatment with drugs alone or a combination treatment
Authors name: Blackburn, 1986
Institution: MRC Brain Metabolism Unit, Royal Edinburgh Hospital
Email:
Address: MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Edinburgh EHIO 5HF (U. K.)
Birgitte Holm Petersen on 31/08/2015 18:37
Select
I:KAT
Kamilla Miskowiak on 06/10/2015 23:46
Outcomes
Jeg har lavet denne remissionsrate data extraction flere gange men den bliver ikke gemt i systemet, så nu giver jeg op. Tallene er i konsekutiv rækkefølge (6, 12, 18 og 24 mdr):COMBI: 16 ad 16, 12 af 16, 14 af 15, 12 af 14Pharma: 7 af 10, 6 af 9, 5 af 9, 5 af 9
Birgitte Holm Petersen on 31/10/2015 00:28
Included
Hovedstudie: Clinical TrialComparative StudyJournal ArticleRandomized Controlled TrialThe efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination.I M Blackburn, S Bishop, A I Glen, L J Whalley, J E ChristieThe British Journal of Psychiatry Sep 1981, 139 (3) 181-189; DOI: 10.1192/bjp.139.3.181
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: 18 years or older, with nonpsychotic, nonbipolar MDD and a score >= 14 on the Hamilton Depression Rating Scale
Excluded criteria: Substance abuse, a serious medical condition, organic psychiatric disorder, severe suicidality, history of psychotic disorder or schizophrenia,
Pretreatment: None
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Sponsorship source: This study was supported by an unrestricted grant from Bristol-Myers Squibb and was partially supported by the Netherlands Organization for Scientific Research grant 451-02-058 to the third author.
Country: The Netherlands
Setting: Three sites participated in the study, all in an urban area. Two of the sites were community mental health clinics, the third an outpatient department of a psychiatric hospital.
Comments:
Authors name: Marc Blom
Institution: Department of Mood Disorders, Parnassia Psychiatric Institute
Email: m.blom@psyq.nl
Address: Department of Mood Disorders, Parnassia Psychiatric InstituteLijnbaan 4NL–2512 VA The Hague (The Netherlands)
Birgitte Holm Petersen on 31/08/2015 18:38
Select
I: IPT
Kamilla Miskowiak on 07/10/2015 07:41
Outcomes
Remission rate: this was neither the first or secondary outcome so not provided in any table. However, they describe that the remission rate (HAMD =< 8 at end of trial) was higher in the combination group than in the drug group alone as demonstrated by logistic regression analyses (see p. 294): for the ITT sample the adjusted OR (95% CI) = 3.22 (1.02-10.12), p=0.045. This indicates that the odds for being remitted was increased by a factor 3.22 in the combination group compared with the drug group only. SHOULD THE AUTHORS BE CONTACTED TO GET THE NUMBERS?
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: Age between 18 and 60 years, DSM-III-R-defined Major Depression (with or without dysthymia), a 17-item HDRS baseline score of at least 14 points and written informed consent
Excluded criteria: Psycho-organic disorder, drug abuse, a psychotic and/or a dissociative disorder; not reliable; communicative problem, too suicidal/ill, contraindication for the antidepressants, treated adequately for current depression, psychotropic medication, pregnancy
Pretreatment: Yes, better quality of life (QLDS) in the combination group than in the drug group at baseline. No other group differences.
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Livskvalitet, Længste follow-up (min. ½ år)
Sponsorship source: This study has been supported by an unrestricted grant from Eli Lilly Nederland.
Country: Netherlands
Setting: Outpatient clinic of the Psychiatrisch Ziekenhuis Amsterdam
Comments:
Authors name: F. de Jonghe
Institution: Mentrum Mental Health Amsterdam
Email: ts-psych@pi.net
Address: Mentrum Mental Health Amsterdam, Department SPDC, Tweede Constantijn Huygenstraat 37, 1054 AG Amsterdam, The Netherlands
Birgitte Holm Petersen on 31/08/2015 18:39
Select
I: dynamisk
Kamilla Miskowiak on 07/10/2015 08:12
Interventions
The table here is missing and I cannot create it. But here is the description of the interventions:Psychotherapy add on to pharma: Short Psychodynamic Supportive Psychotherapy (SPSP): 16 sessions over 24 weeks.Pharmacotherapy (mono): antidepressant drug treatment over 6 months, the protocol involves 3 consecutive steps if the patient doesn't respond: first SSRI, then TCA and finally RIMA.
Kamilla Miskowiak on 07/10/2015 08:22
Outcomes
NB! the values I have typed in are for week 24 (6 months) which was the end of treatment.I had to decide whether to provide the values for the ITT sample or the Observed Cases sample. I chose the ITT sample, given this is in line with the CONSORT guidelines - this is the golden standard for reporting results of RCTS.For the dropout rates given in Table 2, I am unsure if the rates are given in % or in numbers - it says % in the heading of the columns but if you calculate the e.g. 10% or N=57 in the combi group, that gives you 5.7 individuals which cannot be the case??!! Therefore I have typed in n=10 in the box.In the remissions table, I calculated the n based on % in table and total number in the group (N)We miss a table for quality of life (QLDS) and I am not allowed by the system to create one. So I have written them below:QLDS success - Week 24 (end of treatment)Combination group: n=35 out of a total of N=80 in this groupFarma mono group: n=18 out of a total of N=81 in this group
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: ambulante ptt. med ikke-psykotisk, ikke-bipolar depression:1. opfylder RDC's (Research Diagnostic Criteria) kriterier for "major depressive disorder"2. Scorer 20 eller mere på BDI (Beck Depression Inventory)3. Scorer 14 eller mere på Hamiltons rating scale (17 item version)
Excluded criteria: 1. Tidligere eller aktuel RDC skizofreni-diagnose2. Aktuel diagnose med generaliseret angst, panikangst, fobisk angst eller OCD, såfremt disse lidelser dominerer billedet eller også er tilstede udenfor den aktuelle depressive episode3. RDC diagnose med alkoholisme eller stofmisbrug indenfor det sidste år4. Hallucinationer, vrangforestillinger eller stupor5. Suicidalrisiko som nødvendiggør umiddelbar hospitalsindlæggelse6. Anamnese eller laboratorieundersøgelser, som indebærer kontraindikation med imipraminbehandling.7. Manglende respons af imipraminbehandling indenfor de sidste 3 måneder.8. IQ mindre end 80
Pretreatment: 1. Farmakoterapi uden opfølgning2. Farmakoterapi med opfølgning3. Kognitiv terapi4. Farmakoterapi + kognitiv terapi
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Fald i HAM-(17 item) til under 6 og fald i BDI til under 9
Sponsorship source: National Institute of Mental HealthRamsey Foundation
Country: Minnesota, USA
Setting: Department of Psychology, University of Minnesota, Minneapolis
Comments:
Authors name: Steven D Hollon, 1992
Institution: Department of Psychology, University of Minnesota, Minneapolis
Email:
Address:
Birgitte Holm Petersen on 31/08/2015 18:40
Select
I. KAT
Study design:
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: Inclusion criteria were (1) DSM-IVmajor depressive disorder (MDD)17 either chronic (episode duration ≥2 years) or recurrent (with an episode in the past 3 years if only the second episode), (2) 17-item Hamilton Rating Scale for Depression (HRSD) score of 14 or more, (3) age 18 years or older, (4) English speaking, and (5) willing and able to provide informed consent.
Excluded criteria: Exclusion criteria were (1) history of bipolar disorder or nonaffective psychosis, (2) substance dependence in the past 3 months, (3)DSM-IV Axis I disorders requiring nonprotocol treatment, (4) DSM-IV Axis II disorders poorly suited to study treatments (antisocial, borderline, and schizotypal), (5) suicide risk requiring immediate hospitalization, (6) medical condition precluding the use of study medications (including pregnancy), (7) current medications that induce depression, or (8) mandated treatment or compensation issues.
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Sponsorship source: Funding/Support:This study was supported by grants MH60713 and MH01697 (K02) (Dr Hollon),MH60998 (Dr DeRubeis), and MH060768 (DrsFawcett and Zajecka) from the National Institute of Mental Health. Wyeth Pharmaceuticals provided venlafaxine, and Pfizer Inc provided sertraline for the trial.
Country: USA
Setting: Outpatients at research clinics at 3 university medical centers in the United States
Comments:
Authors name: Hollon, 2014
Institution: Department of Psychology, Vanderbilt University
Email: steven.d.hollon@vanderbilt.edu
Address: Department of Psychology, Vanderbilt University, Nashville, TN 37203
Kamilla Miskowiak on 10/09/2015 00:28
Adverse Outcomes
Patients experienced fewer SAEs with ADM plus CT comparedwith ADM alone (49 vs 71; χ1 = 5.76; P = .02). The largestcategories were psychiatric hospitalization (19 vs 29) andmedical hospitalization (22 vs 31). Seven patients made suicideattempts: 3 in theADMplus CT group (twice by 1 person)and 4 in the ADM-alone group. Therewere no completed suicides.There was no significant difference in the rate at whichthose SAEs occurred once time to recovery was taken into account.
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: Ambulante patienter mellem 18 og 65 årDSM-III-R diagnose "major depression"BDI score på 20 eller mereHAM-D (17-item) score på 14 eller mereDysfunctional Attitude Scale score på 155 eller mere
Excluded criteria: epilepsi, organisk hjernesygdom, skizofreni, bipolar sygdom, antisocial personlighedNon-respons defineret som mindre end 25 % reduktion i HAM-D og BDI-score efter 10 uger fører til ekslusion.
Pretreatment: Behandling med Lofepramin i 24 ugerBehandling med Lofepramin + rational-emotive terapi i 24 uger
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Sponsorship source: uoplyst
Country: United Kingdom
Setting:
Comments:
Authors name: Norman D Macaskill
Institution: Department of Psychotherapy, University of Leeds.
Email:
Address: 40 Clarendon Road, Leeds LS2 9PJ, UK
Birgitte Holm Petersen on 31/08/2015 18:42
Select
I: lig KAT
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: Opfylder kriterierne for Depressiv enkeltepisode iflg. DSM-IV-TR.Baseline HAM-D under 15HAM-D under 7 efter ½ års behandling med enten farmakoterapi eller farmakoterapi + psykoterapi.Tilstedeværelse af fokale problemer eller nylig trigger i form af negativ life event18-65 år
Excluded criteria: Mental retarderingAnamnese med organisk mental lidelse, psykose eller bipolar sygdomSvær akse II patologi (personlighedsforstyrrelser)Svær neurologisk eller fysisk sygdomMisbrugKontraindikationer mod de anvendte antidepressivaSufficient behandling af depression inden undersøgelses-startBehov for anden psykofarmaka end de i protokollen anførteSuicidalrisiko
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Tid til recidiv og HAM-D score
Sponsorship source: ingen
Country: Italien
Setting:
Comments:
Authors name: Guiseppe Maina
Institution: Department of Neurosciences, Mood and Anxiety Disorders Unit, University of Turin, Turin, Italy
Email:
Address: University of Turin, Department ofNeurosciences, Via Cherasco 11 – 10126 Torino, Italy.
Birgitte Holm Petersen on 31/08/2015 18:42
Select
I: dynamisk
Ellen Margrethe Christensen on 12/10/2015 18:42
Study Design
prospektiv, longitudinelt follow up over 2 år
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
BDT i 16 uger, opfølgning i 12 måneder
Included criteria: ambulante patienteraler over 18 årPatienten opfylder DSM-IV kriterier for pirmær OCD med "major depression"OCD-symptomer skal have været til stede i mindst 1 år før inklusion i undersøgelsenY-BOCS over/lig med 16 ved baselineHAM-D (17 item) over/lig med 15 ved baselineAccept af psykoterapeutisk behandlingTilstedeværelse af fokale problemer og/eller nylig udløsende livsbegivenhed
Excluded criteria: a lifetime diagnosis of bipolar disorder, schizophrenia, other psychotic disorders, mental retardation or drug abuse;an organic brain syndrome or medical illness that would contraindicate the use of fluvoxamine or sertraline;a severe axis II psychopathology (cluster A personalitydisorder, antisocial personality disorder and borderline personalitydisorder according to the DSM-IV) that would contraindicate the treatment with BDT;pregnant or nursing women andwomen of childbearing potential not using adequate contraceptive measuresongoing psychological treatment.
Pretreatment: 1. standard SSRI farmakoterapi2. standard SSRI farmakoterpi + brief dynamic therapy
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
BDT i 16 uger, opfølgning i 12 måneder
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
primær: fald i HAM-D og Y-BOCS. sekundær: fald i CGI og GAF
Sponsorship source: ikke oplyst
Country: Italien
Setting:
Comments:
Authors name: Prof. Giuseppe Maina
Institution: Department of Neurosciences, Mood and Anxiety Disorders Unit, University of Turin
Email: giuseppemaina @ hotmail.com
Address: Via Cherasco 11IT–10126 Turin (Italy)
Birgitte Holm Petersen on 31/08/2015 18:42
Select
I: dynamisk
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: between 19 and 40 years of age, had an infant > 2 months and < 8 months of age, born after a full-term pregnancy, with no congenital abnormalities, a screening EPDS score of ⩾ 13, DSM-IV diagnosis of a depressive disorder
Excluded criteria: pregnancy; concurrent psychiatric disorder; antidepressant usage in past month; major allergy or drug allergy; substance abuse; non-response to sertraline or to adequate trials of two SSRIs; a predisposition to headache, migraine or nausea.... se note!
Pretreatment: no
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Sponsorship source: The study was funded through a grant from Pfizer Inc. and by theKinsman Fund. Neither funding body had any input into the studydesign, the analysis or interpretation of results, or the decision topublish the findings.
Country: Australia
Setting: Maternal and Child Health Centres in Melbourne, Victoria.
Comments:
Authors name: Milgrom
Institution: Parent-Infant Research Institute , Department of Clinical & Health Psychology, Heidelberg Repatriation Hospital and Melbourne School of Psychological Sciences, University of Melbourne
Email: jeannette.milgrom@austin.org.au
Address: Parent-Infant Research Institute , Department of Clinical & Health Psychology, Heidelberg Repatriation Hospital, Heidelberg West, Australia and Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia
Kamilla Miskowiak on 06/10/2015 18:46
Population
Exclusion criteria (could not be entered into the exclusion criteria box): pregnancy; concurrent psychiatric disorder; antidepressant usage in past month; major allergy or drug allergy; substance abuse; non-response to sertraline or to adequate trials of two SSRIs; a predisposition to headache, migraine or nausea; tobacco habit in excess of 10 cigarettes per day; caffeine consumption in excess; ongoing dental work; psychotic depression; or suicidal intent; participation in medical trial within the previous 3 months; unwilling a priori to engage in either of the mono-therapies or in the combination therapy
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: diagnosis of major depressive disorder according to the Diagnostic Interview Schedule (20),Beck Depression Inventory (21) score greater than 17Modified Hamilton Rating Scale for Depression (17-item) score greater than 17age between 18 and 65 years.
Excluded criteria: a concurrent diagnosis of bipolar disorder, alcohol dependence or drug dependence, schizophrenia, somatization disorder, antisocial personality disorder, or organic brain syndromemedical illness of a type or severity that might contraindicate administration of tricyclic antidepressants or might produce substantial depressive symptomsrecent use of medication known to result in depressive symptoms.
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
BDI, HAM-D, suicidalscala
BDI, HAM-D, suicidal-skala
Sponsorship source: NIMH, Biomedical Research, Support Grant RR-058 17 to Butler Hospital from NIH,A grant from the Firan Foundation.
Country: Rhode Island, USA
Setting:
Comments:
Authors name: Ivan W. Miller
Institution: Department of Psychiatry and Human Behavior, Brown University and Butler Hospital,
Email:
Address: Butler Hospital, 345 Blackstone Blvd., Providence, RI 02906.
Birgitte Holm Petersen on 31/08/2015 18:42
Select
I. KAT
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
5 ugers IPT, opfølgning efter 3 og 12 måneder
Included criteria: 18 and 65 years of age1. primary diagnosis of major depression (single-episode, recurrent, or bipolar II) according to the Structured Clinical Interview for DSM-IV (17) (SCID)2. score of ≥16 on the 17-item version of the Hamilton Depression Rating Scale (HAMD)
Excluded criteria: 1) concurrent diagnosis of bipolar I disorder, primary substance abuse or dependency, other primary axis I disorders, mental disorder because of organic factors, and borderline or antisocial personality disorder; 2) psychotic symptoms; 3) severe cognitive impairment; 4) contraindications to the study medication; 5) being actively suicidal.
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
5 ugers IPT, opfølgning efter 3 og 12 måneder
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
ændring i Ham-D, BDI, GAF
Sponsorship source: German Research Society, Bonn, Germany.
Country: Tyskland
Setting:
Comments:
Authors name: Elisabeth Schramm
Institution: Departments of Psychiatry, Psychotherapy, and Psychology, University of Freiburg, Freiburg, Germany
Email: Elisabeth.Schramm@uniklinik-freiburg.de
Address: University Medical Center Freiburg, Department of Psychiatry and Psychotherapy, Hauptstrasse 5, 79104 Freiburg, Germany;
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: 18 to 65 year old inpatientsA minimum score of 16 on the 17-item version of the Hamilton Rating Scale for DepressionDiagnosis of MDD according to the Structured Clinical Interview for DSM IV
Excluded criteria: A history of bipolar I disorder or psychotic symptoms, substance dependency, a mental disorder due to organic factors, a borderline or antisocial personality disorder or if they had another Axis I diagnosis that was primary.Contraindications to the study medicationActively suicidal
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
Reduktion i HAM-D
Respons, Efter endt behandling
Sponsorship source: German Research Society, Bonn, Germany
Country: Tyskland
Setting:
Comments:
Authors name: Elisabeth Schramm
Institution: Department of Psychiatry and Psychotherapy, University of Freiburg, Germany
Email: Elisabeth.Schramm@uniklinik-freiburg.de
Address: Department of Psychiatry and Psychotherapy, University of Freiburg, Germany
Birgitte Holm Petersen on 31/08/2015 18:49
Select
I: IPT
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: age between 18 and 60 yearsfulfill diagnostic criteria for primary affective disorder (unipolar, depressed type), score 20 or higher on the BDIscore 14 or higher on the Hamilton Rating Scale for Depression (HRSD)12 (17-item version). diagnosis of primary affective disorder was made using the National Institute of Mental Health Diagnostic Interview Schedule.
Excluded criteria: in need of hospitalizationcurrently receiving psychotropic medicationunwilling to accept random assignment to one of four groups
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Funktionsevne (aktivitet og deltagelse), Længste FU (min. ½ år)
Recidivrate, Længste follow-up (min. ½ år)
ændring i BDI
Sponsorship source: the National Institute of Mental Health, Bethesda, Md.
Country: Pennsylvania, USA
Setting:
Comments:
Authors name: Anne D. Simons
Institution: Western Psychiatric Institute and Clinic and the Department of Psychiatry, University of Pittsburgh School of Medicine (Dr Simons), and the Department of Psychiatry, Washington University School of Medicine,St Louis (Drs Murphy, Levine, and Wetzel).
Email:
Address: Western Psychiatric Institute and Clinic, 3811O'Hara St, Pittsburgh, PA 15213.
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: MDD (SCID),HRSD≥17
Excluded criteria: cognitiveimpairment (MMHE), otherADM therapy
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Recidivrate, Længste follow-up (min. ½ år)
Livskvalitet, Længste follow-up (min. ½ år)
Responsrate, Efter endt behandling
Arbejdsfastholdelse, Længste follow-up (min. ½ år)
Sponsorship source: National Alliancefor Research inSchizophrenia and Affective Disorders, NIMH
Country: US
Setting:
Comments:
Authors name: Sirey 2005
Institution:
Email:
Address:
Birgitte Holm Petersen on 31/08/2015 18:52
Select
I: lig KAT
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: diagnosis of nonbipolar,non-psychotic acuteprimary MD according toSADS and RDC
Excluded criteria: otherpredominant disorders,organic brain syndrome,alcohol abuse,schizophrenia, mania, nonrespondersto previousweekly psychotherapy
Pretreatment:
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Remissionsrate, Efter endt behandling
Selvmordsadfærd, Længste FU (min. ½ år)
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Recidivrate, Længste follow-up (min. ½ år)
Livskvalitet
Responsrate, Efter endt behandling
Arbejdsfastholdelse, Længste follow-up (min. ½ år)
Sponsorship source: Clinical ResearchBranch, National Instituteof Mental Health
Country: US
Setting:
Comments: Artiklen har kun data på 1 års FU, artikel på end of treatment er bestilt, men ikke i hus endnu.OBS Selvmordsadfærd= suicide attempts og suicide.Der er en social adjustment scale , der indeholder en subscale med 'Work' måske kan den bruges?
Authors name: Weissman 1981
Institution:
Email:
Address:
Birgitte Holm Petersen on 31/08/2015 18:53
Select
I: IPT
Britta Tendal on 11/11/2015 02:53
Outcomes
Selvmordsadfærd= suicide attempts og suicide
Britta Tendal on 11/11/2015 02:57
Included
Mangler et paper på end of treatment, den er bestilt
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: Aged 18–75 years, adherence to an adequate dose of antidepressant medication for at least 6 weeks and had a Beck depression inventory (BDI-II) 17 score of >=14. ICD-10 criteria for a depressive episode
Excluded criteria: bipolar disorder, psychotic disorder, major alcohol or substance abuse, were unable to complete the questionnaires; or were pregnant, receiving CBT or other psychotherapy for their depression, or who received CBT in the past 3 years, part of other study
Pretreatment: The intervention group included more men, more individuals in paid employment and more who reported financial difficulty,fewer individuals with caring responsibilities or longstanding illness or disability, and better physical function
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Livskvalitet physical subscale of SF
Sponsorship source: National Institute for Health Research Health Technology Assessment (The funding source had no role in study design, datacollection, data analysis, interpretation of data, or writing of the report)
Country: United Kingdom
Setting: In patient’s general practice surgery or at nearby National Health Service (NHS) or university premises
Comments:
Authors name: Nicola Wiles
Institution: Centre for Mental Health, Addiction and Suicide Research, School of Socialand Community Medicine, University of Bristol
Email: nicola.wiles@bristol.ac.uk
Address: Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK
Study design: Randomized controlled trial
Study grouping: Parallel group
Open Label:
Cluster RCT:
Baseline Characteristics
Psykoterapi add on farma
Farma monobehandling
Included criteria: (1) a diagnosis of non-psychotic DSM-IV MDD ascertained by the Mini InternationalNeuropsychiatric Interview (MINI) (Sheehan et al., 1998;Si et al.,2009); (2) age between 17 and 60 years; (3) length of illness lessthan 1 year; (4) total score of the 17-item Hamilton Rating Scalefor Depression (HAMD)–Chinese version (Hamilton, 1960;Xieand Shen, 1984)Z17 (moderate–severe depression); (5) Ability tocommunicate and provide a written consent form; and (6) havingat least one family member cohabitating with the patient
Excluded criteria: Exclusion criteria included (1) current or past historyof any other psychiatric disorders including drug and alcoholicdependence; (2) ongoing acute medical and neurological condi-tions; (3) lack of response to citalopram, sertraline, or paroxetineand CBT in the past; (4) taking an antipsychotic medication ormood stabilizer; and (5) having suicidal ideation, suicide plan orattempt in the current depressive episode
Pretreatment: No
Intervention Characteristics
Psykoterapi add on farma
Farma monobehandling
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Livskvalitet, Længste FU (min. ½ år)
Remissionsrate, Efter endt behandling
Recidivrate, Længste FU (min. ½ år)
Arbejdsfastholdelse, Længste FU (min. ½ år)
Selvmordsadfærd, Længste FU (min. ½ år)
Responsrate, Efter endt behandling
Hospitalsindlæggelser (antal), Længste FU (min. ½ år)
Frafald/ All-cause discontinuation, Ved interventionens afslutning
Arbejds- og social tilpasning (WSAS)
Sponsorship source: This study was funded by the National Key Scientific and Technological Projects for the 11th 5-Year from the Ministry of Science and Technology of China (Project Title: Early Diagnostic Assessment and Standardized Treatment Approach forDepression; No. 2007BAI17B05) and the Project of the Beijing Municipal Science andTechnology Commission (Grant no. D090507046410011)
Country: China
Setting: Outpatients from a university-affliated teaching hospital in Beijing
Comments: No protocol available
Authors name: Two first author Si Zu and Yu-Tao Xiang (contact)
Institution: Department of Psychiatry, Chinese University of Hong Kong
Email: xyutly@gmail.com, lizhj8@ccmu.edu.cn
Address: Department of Psychiatry, Chinese University of Hong Kong, Ground Floor,Multicentre, Tai Po Hospital, Tai Po, N.T., Hong Kong,China.
Britta Tendal on 04/11/2015 20:44
Outcomes
WSAS Jeg har taget final værdier, der er også rapporteret change
Wrong patient population
Wrong intervention
Wrong indication
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCE
KCE
KCE
KCE
Primær
Primær
KCE
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCE
KCE
KCE
KCE
Primær
Primær
KCE
Performance bias due to knowledge of the allocated interventions by participants and personnel during the study
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCE
KCE
KCE
KCE
Primær
Not assessed?
KCE
Detection bias due to knowledge of the allocated interventions by outcome assessors
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCE
KCE
KCE
KCE
Primær
Primær
KCE
Attrition bias due to amount, nature or handling of incomplete outcome data
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCE
KCE
KCE
KCE
Primær
Primær
KCE
Reporting bias due to selective outcome reporting
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCE
KCE
KCE
KCE
Primær
Primær
KCE
Bias due to problems not covered elsewhere in the table
KCE
KCE
KCE
Primær
KCE
KCE
KCE
Primær
KCE
KCE
KCe
KCE
KCE
KCE
Primær
Primær
KCE